NGS Group (NGS) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
6 Nov, 2025Executive summary
Net sales for Q3 2025 were 68 MSEK, down 18% year-over-year, mainly due to a weaker healthcare staffing market driven by political decisions reducing demand from regions.
EBITA improved to 0.9 MSEK from -2.4 MSEK in Q3 2024, with a positive trend also seen for the January–September period.
A new CEO was appointed, and a new brand, Human Capital, was launched for the executive search and recruitment segment.
Financial highlights
Q3 net sales: 68 MSEK (83 MSEK in Q3 2024), an 18% decrease.
Q3 EBITA: 0.9 MSEK (-2.4 MSEK in Q3 2024); EBIT margin: 1.3% (-2.9%).
Q3 net income: 0.4 MSEK (-2.7 MSEK in Q3 2024); EPS: 0.02 SEK (-0.11 SEK).
January–September net sales: 216 MSEK (263 MSEK in 2024), down 18%.
January–September EBITA: 0.9 MSEK (-23.0 MSEK in 2024); net income: -1.0 MSEK (-70.2 MSEK).
Cash flow from operations Q3: -3.2 MSEK (-7.9 MSEK); January–September: -11.0 MSEK (-25.3 MSEK).
Outlook and guidance
The company aims for 10% organic and acquired net sales growth over time, an EBITA margin of 4%, and a dividend payout of 40–50% of net profit, subject to financial position.
Management remains optimistic about the year-end, despite ongoing market challenges.
Latest events from NGS Group
- EBITA turned positive in 2025, but goodwill write-down led to a net loss and no dividend.NGS
Q4 202526 Feb 2026 - EBITA returned to positive in Q2 2025 amid revenue decline and challenging market conditions.NGS
Q2 20257 Aug 2025 - Q3 sales dropped 27% but profitability and equity ratio improved amid market challenges.NGS
Q3 202413 Jun 2025 - Sharp revenue decline and heavy losses in H1 2024; cost cuts and new deals target recovery.NGS
Q2 202413 Jun 2025 - EBITA improved despite a 20% sales drop, driven by cost control and business divestment.NGS
Q1 20256 Jun 2025 - Q4 EBITA returned to profit despite lower sales, driven by cost control and segment focus.NGS
Q4 20245 Jun 2025